A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension
CONCLUSIONS: This review adds to growing evidence supporting the efficacy, safety, and tolerability of FDC bisoprolol and amlodipine in managing hypertension.PMID:35510372 | DOI:10.1080/03007995.2022.2072087 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - May 5, 2022 Category: Research Authors: Ulrike Hostalek-Gottwald Zbigniew Gaciong Source Type: research
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. O... (Source: Trials)
Source: Trials - April 14, 2022 Category: General Medicine Authors: Seonaidh Cotton, Graham Devereux, Hassan Abbas, Andrew Briggs, Karen Campbell, Rekha Chaudhuri, Gourab Choudhury, Dana Dawson, Anthony De Soyza, Shona Fielding, Simon Gompertz, John Haughney, Chim C. Lang, Amanda J. Lee, Graeme MacLennan, William MacNee & Tags: Study protocol Source Type: research
In vitro Effects of Thirty-eight Cardiac Drugs on Human Serum Paraoxonase
In this study, the effects of 38 commonly used cardiac drugs on the human paraoxonase (PON1) were investigated. PON1 was purified from human serum blood by ammonium sulfate precipitation (60-80%) and hydrophobic interaction chromatography (Sepharose4B~L-tyrosine~1-napthylamine gel). All of the cardiac drugs inhibited PON1 at the micro molar level. IC50 and Ki values were determined for each drug. The tested drugs displayed potent PON1 inhibitory activity. It was found that the weakest PON1 inhibitors are Irbesartan (Ki: 421.73 µM), Glyceryl Trinitrate (Ki: 351.48 µM) and Apixaban (Ki: 333.27 µM). Bisoprolol hemifumarate...
Source: Atherosclerosis - April 8, 2022 Category: Cardiology Authors: Onur Argan Kubra Cikrikci Harun Uslu Nahit Gencer Source Type: research
Amoxicillin/clavulanic acid-associated severe neutropenia
A 72-year-old man presented with an abnormal blood count and was admitted. His history included hypertension and hyperlipidaemia with an old myocardial infarction and mild stroke; liver cirrhosis due to non-alcoholic steatohepatitis (NASH) with hypersplenism and oesophageal varices but no ascites, oedema or bleeding; and benign prostatic hypertrophy. His medications (unchanged for years) included furosemide, spironolactone, bisoprolol, rosuvastatin, alfuzosin and omeprazole. Two weeks prior, he was discharged from our department after left leg cellulitis and Streptococcus pyogenes bacteraemia responsive to parenteral clind...
Source: Postgraduate Medical Journal - March 22, 2022 Category: General Medicine Authors: Schattner, A., Dubin, I. Tags: Adverse drug reactions Source Type: research
Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study
To evaluate the role of bisoprolol to control symptoms and left ventricular outflow tract obstruction (LVOTO) in a consecutive cohort of adults with hypertrophic cardiomyopathy (HCM). (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - March 9, 2022 Category: Cardiology Authors: Emanuele Monda, Michele Lioncino, Giuseppe Palmiero, Francesco Franco, Marta Rubino, Annapaola Cirillo, Federica Verrillo, Adelaide Fusco, Martina Caiazza, Marialuisa Mazzella, Elisabetta Moscarella, Francesca Dongiglio, Joseph Sepe, Giuseppe Pacileo, Pao Source Type: research
Effectiveness of bisoprolol versus other β-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink
Conclusion: No differences in BP variation and safety outcomes.PMID:35189710 | DOI:10.2217/cer-2021-0305 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - February 22, 2022 Category: General Medicine Authors: Caroline Foch Arthur Allignol Thilo Hohenberger Emmanuelle Boutmy Stephan Schaefer Ulrike Hostalek Source Type: research
Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
Curr Atheroscler Rep. 2022 Feb 16. doi: 10.1007/s11883-022-00983-2. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Current guidelines for the management of arterial hypertension endorse β-adrenergic receptor blocking agents (beta-blockers, BBs) as being particularly useful for hypertension in specific situations such as symptomatic angina, tachycardia, post-myocardial infarction, heart failure with reduced ejection fraction (HFrEF), and as an alternative to angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in hypertensive women planning pregnancy or at least of child-bearing potentia...
Source: Atherosclerosis - February 17, 2022 Category: Cardiology Authors: Michal Vrablik Alberto Corsini Eva T ůmová Source Type: research
Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
Curr Atheroscler Rep. 2022 Feb 16. doi: 10.1007/s11883-022-00983-2. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Current guidelines for the management of arterial hypertension endorse β-adrenergic receptor blocking agents (beta-blockers, BBs) as being particularly useful for hypertension in specific situations such as symptomatic angina, tachycardia, post-myocardial infarction, heart failure with reduced ejection fraction (HFrEF), and as an alternative to angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in hypertensive women planning pregnancy or at least of child-bearing potentia...
Source: Atherosclerosis - February 17, 2022 Category: Cardiology Authors: Michal Vrablik Alberto Corsini Eva T ůmová Source Type: research
Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
Abstract Purpose of ReviewCurrent guidelines for the management of arterial hypertension endorse β-adrenergic receptor blocking agents (beta-blockers, BBs) as being particularly useful for hypertension in specific situations such as symptomatic angina, tachycardia, post-myocardial infarction, heart failure with reduced ejection fraction (HFrEF), and as an alternative to angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in hypertensive women planning pregnancy or at least of child-bearing potential. One of the most common uses of BBs is in patients with a recent myocardial infarction,...
Source: Current Atherosclerosis Reports - February 16, 2022 Category: Cardiology Source Type: research
Erratum: Metoprolol and bisoprolol ameliorate hypertrophy of neonatal rat cardiomyocytes induced by high glucose via the PKC/NF- κB/c-fos signaling pathway
Exp Ther Med. 2022 Mar;23(3):211. doi: 10.3892/etm.2022.11134. Epub 2022 Jan 10.ABSTRACT[This corrects the article DOI: 10.3892/etm.2019.8312.].PMID:35126714 | PMC:PMC8796277 | DOI:10.3892/etm.2022.11134 (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - February 7, 2022 Category: General Medicine Authors: Min Wang Qingbo Lv Liding Zhao Yao Wang Yi Luan Zhengwei Li Guosheng Fu Wenbin Zhang Source Type: research
